[go: up one dir, main page]

PE20090798A1 - Derivados de benzotiazol como moduladores del receptor de grelina - Google Patents

Derivados de benzotiazol como moduladores del receptor de grelina

Info

Publication number
PE20090798A1
PE20090798A1 PE2008001752A PE2008001752A PE20090798A1 PE 20090798 A1 PE20090798 A1 PE 20090798A1 PE 2008001752 A PE2008001752 A PE 2008001752A PE 2008001752 A PE2008001752 A PE 2008001752A PE 20090798 A1 PE20090798 A1 PE 20090798A1
Authority
PE
Peru
Prior art keywords
greline
receptor modulators
benzothiazol
benzamide
halo
Prior art date
Application number
PE2008001752A
Other languages
English (en)
Inventor
Jack Mac Queen Allen
Roger John Butlin
Clive Green
William Mccoull
Graeme Richard Robb
James Matthew Wood
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090798A1 publication Critical patent/PE20090798A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENZOTIAZOL DE FORMULA (I) DONDE R1 ES HALO, NITRO, ALQUENILO(C2-C6), CICLOALQUILO(C3-C6), ENTRE OTROS; R2 ES H, HALO, ALQUINILO(C2-C6), CICLOALQUILO(C3-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6), ALCOXI(C1-C4)-ALQUILO(C1-C4), ENTRE OTROS; R4 ES HALO, ALQUILO(C1-C4), ALCOXI(C1-C4), NITRO, ENTRE OTROS; m ES DE 0 A 3. SON COMPUESTOS PREFERIDOS: 2-CLORO-N-[[6-(2-MORFOLIN-4-ILETILSULFONIL)BENZOTIAZOL-2-IL]CARBAMOIL]BENZAMIDA, 2-CLORO-N-[[6-[2-(2-METOXIETILAMINO)ETILSULFONIL]BENZOTIAZOL-2-IL]CARBAMOIL]-BENZAMIDA, 2-CLORO-N-[[6-(2-DIMETILAMINOETILSULFONIL)BENZOTIAZOL-2-IL]CARBAMOIL]BENZAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR DE GRELINA SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, TRASTORNOS ALIMENTARIOS, DIABETES
PE2008001752A 2007-10-10 2008-10-10 Derivados de benzotiazol como moduladores del receptor de grelina PE20090798A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97888907P 2007-10-10 2007-10-10

Publications (1)

Publication Number Publication Date
PE20090798A1 true PE20090798A1 (es) 2009-07-23

Family

ID=40343627

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001752A PE20090798A1 (es) 2007-10-10 2008-10-10 Derivados de benzotiazol como moduladores del receptor de grelina

Country Status (30)

Country Link
US (4) US20110124621A1 (es)
EP (2) EP2205576A1 (es)
JP (1) JP5357884B2 (es)
KR (1) KR20100064380A (es)
CN (1) CN101883762A (es)
AR (1) AR068782A1 (es)
AU (1) AU2008309378B2 (es)
BR (1) BRPI0818598A2 (es)
CA (1) CA2702181A1 (es)
CL (1) CL2008003024A1 (es)
CO (1) CO6270319A2 (es)
CR (1) CR11360A (es)
CU (1) CU23899B1 (es)
DO (1) DOP2010000102A (es)
EA (1) EA201000439A1 (es)
EC (1) ECSP10010168A (es)
HN (1) HN2010000655A (es)
IL (1) IL204612A0 (es)
MX (1) MX2010003761A (es)
MY (1) MY150046A (es)
NI (1) NI201000051A (es)
NZ (1) NZ584281A (es)
PE (1) PE20090798A1 (es)
SA (1) SA08290626B1 (es)
SV (1) SV2010003526A (es)
TW (1) TW200924758A (es)
UA (1) UA100527C2 (es)
UY (1) UY31383A1 (es)
WO (1) WO2009047558A1 (es)
ZA (1) ZA201002268B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
EP2205584A1 (en) 2007-10-10 2010-07-14 Novartis Ag Spiropyrrolidines and their use against hcv and hiv infection
US9126938B2 (en) 2009-08-17 2015-09-08 The Brigham And Women's Hospital, Inc. Phosphatidylcholine transfer protein inhibitors
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
WO2013049407A2 (en) * 2011-09-30 2013-04-04 Kineta, Inc Anti-viral compounds
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP3390355B1 (en) 2016-03-22 2022-12-28 Helsinn Healthcare S.A. Benzenesulfonyl-asymmetric ureas and medical uses thereof
WO2020036133A1 (ja) * 2018-08-17 2020-02-20 クミアイ化学工業株式会社 ３－（１ｈ－１，２，４－トリアゾール－１－イル）安息香酸アミド誘導体及び有害生物防除剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225169A (ja) 1985-03-30 1986-10-06 Nippon Tokushu Noyaku Seizo Kk 新規ベンゾイルウレア、その製法及び殺虫剤
JP3126541B2 (ja) * 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US6884876B2 (en) 2001-01-17 2005-04-26 Korea Research Institute Of Chemical Technology Disperse-reactive dyes containing acetoxyethylsulfone or vinylsulfone and their process
WO2005025567A1 (en) * 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Benzothiazole derivatives for the treatment of diabetes
US20050070712A1 (en) 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
US20050171131A1 (en) * 2003-09-26 2005-08-04 Christi Kosogof Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators

Also Published As

Publication number Publication date
CL2008003024A1 (es) 2010-01-15
JP2011500546A (ja) 2011-01-06
BRPI0818598A2 (pt) 2017-05-16
CA2702181A1 (en) 2009-04-16
CO6270319A2 (es) 2011-04-20
US20110124621A1 (en) 2011-05-26
JP5357884B2 (ja) 2013-12-04
AU2008309378B2 (en) 2012-03-08
CU20100063A7 (es) 2011-10-05
WO2009047558A1 (en) 2009-04-16
US20090186870A1 (en) 2009-07-23
ECSP10010168A (es) 2010-06-29
MY150046A (en) 2013-11-29
ZA201002268B (en) 2011-10-26
CR11360A (es) 2010-07-15
CU23899B1 (es) 2013-06-28
US20130203730A1 (en) 2013-08-08
HN2010000655A (es) 2012-11-12
EA201000439A1 (ru) 2011-04-29
NZ584281A (en) 2012-03-30
NI201000051A (es) 2012-05-15
IL204612A0 (en) 2010-11-30
MX2010003761A (es) 2010-04-21
SV2010003526A (es) 2010-09-13
AR068782A1 (es) 2009-12-02
EP2205576A1 (en) 2010-07-14
TW200924758A (en) 2009-06-16
CN101883762A (zh) 2010-11-10
UY31383A1 (es) 2009-05-29
KR20100064380A (ko) 2010-06-14
SA08290626B1 (ar) 2011-06-22
EP2607357A1 (en) 2013-06-26
DOP2010000102A (es) 2010-04-30
UA100527C2 (en) 2013-01-10
US20120115845A1 (en) 2012-05-10
AU2008309378A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
PE20090798A1 (es) Derivados de benzotiazol como moduladores del receptor de grelina
PE20141375A1 (es) Activadores de glucoquinasa
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20091008A1 (es) Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20142099A1 (es) Derivados de sulfonamida
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20011259A1 (es) Derivado de piridina y pirimidina
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20141681A1 (es) Inhibidores de btk
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20091425A1 (es) Derivados de aminotiazol
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
PE20090773A1 (es) Derivados de morfolina pirimidina
AR057661A1 (es) Un derivado de oxima y sus preparaciones
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20081217L (no) Nye benzotiazolonderivater
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed